Grafton Optical is proud to announce the launch of the I-PEN® Tear Film Osmolarity System by I-Med Pharma - the new standard for diagnosing Dry Eye Disease.
Exclusively available in the UK through Grafton Optical, the I-PEN® is the world’s first, hand-held, point-of-care, solid state electronic diagnostic device to detect and indirectly measure the elevated tear film osmolarity levels associated with mild, moderate and severe Dry Eye Disease.
• Quantitative measurement of osmolarity • Affordable point-of-care test • Quick and simple to use (takes less than 5 seconds per eye) • Reproducible, accurate and reliable results • Uses Single-Use-Sensors (SUS)
The I-PEN® is designed for use as an in-practice screening device both for patients presenting with dry eye symptoms and for all pre-and post-surgical patients. In addition, the I-PEN® is an invaluable asset for monitoring the progress of dry eye treatment therapies. The I-PEN® is for professional in-vivo diagnostic use only.
The I-PEN® complements Grafton’s growing portfolio of Dry Eye Disease diagnosis and treatment products and devices and will debut at Optrafair 2018 in the Grafton Dry Eye Centre on Stand C54.
The Centre will showcase Grafton’s growing product range and will provide a one-stop-shop for optometrists and ophthalmologists wishing to offer their clients a specialist Dry Eye service.
Dry Eye disease is increasingly gaining momentum, both in its reported prevalence and its coverage in the industry media. More and more practices are now diversifying to incorporate services to diagnose, treat and manage the disease as they learn the significant benefits not only to their patients but also to their income.
The Grafton range of products provide a lucrative revenue stream for practices, providing diagnosis and treatment to sufferers of this growing condition which accounts for at least 30% of a practices patient demographic.
For more information on the I-PEN® or to arrange a demonstration please contact email@example.com or call us on +44 (0)1923 233980.